Valacyclovir has no proven benefit for treating an active COVID-19 infection. It was designed to fight herpesviruses (the viruses behind cold sores, shingles, and genital herpes) and does not target SARS-CoV-2, the virus that causes COVID-19. However, researchers are investigating whether valacyclovir might play a narrow role in long COVID, not by attacking the coronavirus itself, but by addressing a secondary problem it can trigger.
Why Valacyclovir Doesn’t Treat COVID-19 Directly
Valacyclovir works by interfering with how herpesviruses copy their DNA. SARS-CoV-2 is a completely different type of virus. It’s an RNA virus with a different replication process, so valacyclovir has no meaningful ability to slow it down or clear it from your body. Antivirals approved for acute COVID-19, such as Paxlovid, were specifically designed to block the enzymes SARS-CoV-2 uses to replicate. Valacyclovir simply doesn’t have that capability.
No large clinical trials have shown that taking valacyclovir during an active COVID-19 infection reduces symptom severity, shortens illness duration, or lowers the risk of hospitalization.
The Long COVID Connection
Where valacyclovir enters the COVID conversation is through long COVID research, and the connection is indirect. One leading theory about why some people develop lingering symptoms (fatigue, brain fog, pain) weeks or months after their initial infection is that COVID-19 weakens the immune system enough to let dormant viruses wake back up. Most adults carry at least one herpesvirus quietly in their body for life. Under normal circumstances the immune system keeps these viruses in check, but the stress of a COVID-19 infection can allow them to reactivate.
This reactivation of herpesviruses, including Epstein-Barr virus and others, has been documented in multiple studies of long COVID patients. The idea is that these reawakened viruses may be contributing to or even driving some of the persistent symptoms people experience. Since valacyclovir is effective against herpesviruses, researchers are testing whether suppressing that reactivation could relieve long COVID symptoms.
What the Research Shows So Far
The evidence is still very early. A combination called IMC-2, which pairs valacyclovir with celecoxib (an anti-inflammatory pain reliever), has been studied in a small case series of long COVID patients. Published in Frontiers in Immunology, that report documented patient-reported improvements, but case series are among the weakest forms of evidence. They lack control groups, involve small numbers of people, and rely on self-reported outcomes rather than objective measurements.
A more rigorous clinical trial registered on ClinicalTrials.gov is testing this same valacyclovir-celecoxib combination specifically in adult female patients with long COVID. As of the most recent update, that trial has not posted results. Until controlled trials are completed and peer-reviewed, there’s no reliable way to know whether the combination actually works better than a placebo, or whether valacyclovir contributes meaningfully on its own versus celecoxib doing the heavy lifting.
It’s also worth noting that in the research so far, valacyclovir is being studied as part of a combination, not as a standalone treatment for long COVID. Whether it would offer any benefit on its own for long COVID symptoms remains untested in a formal trial setting.
Safety Considerations
Valacyclovir is generally well tolerated for its approved uses, but it does carry risks, particularly for your kidneys. The clinical trial studying it for long COVID specifically excludes people with kidney disease, a history of acute kidney injury within the past year, or anyone whose kidneys filter below a certain threshold. This reflects a known concern: valacyclovir is processed by the kidneys, and in people with reduced kidney function, the drug can accumulate to harmful levels.
People with a history of allergic reactions to acyclovir, famciclovir, or related antiviral medications are also excluded from the trial. Common side effects of valacyclovir at standard doses include headache, nausea, and abdominal pain. At higher or prolonged doses, the risk of kidney-related problems increases.
What This Means Practically
If you’re dealing with an active COVID-19 infection, valacyclovir is not the right medication. Treatments specifically designed for SARS-CoV-2 exist and have been tested in large trials. If you’re experiencing persistent symptoms months after a COVID infection and suspect herpesvirus reactivation might be involved, that’s a conversation worth having with a healthcare provider who can test for reactivation markers and weigh the risks and benefits based on your specific situation. Taking valacyclovir on your own for COVID or long COVID, outside of medical supervision, is not supported by current evidence and carries real kidney risks, especially with prolonged use.